Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Quinine or its salts or derivativesPDL

except when sold in oral dosage form that provides 50 mg or less of quinine base per dosage unit or per daily dose

I DEC / 13
Quinupristin or its saltsPDL I DEC / 13
Rabeprazole or its saltsPDL I DEC / 13
Rabies immune globulin I FEB / 02
Rabies vaccine I FEB / 02
Racemethionine II SEP / 98
RacemethorphanN I JUN / 02
RacemoramideN I JUN / 02
RacemorphanN I JUN / 02
Raloxifene or its saltsPDL I DEC / 13
Raltegravir or its saltsPDL I DEC / 13
Raltitrexed or its salts or derivativesPDL

including but not limited to raltitrexed disodium

I DEC / 13
Ramipril or its salts or derivativesPDL I DEC / 13
RamucirumabPDL I OCT / 15
RanibizumabPDL I DEC / 13
Ranitidine or its saltsPDL

except when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn for human use

I DEC / 13
Ranitidine or its salts. when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 4,500 mg of ranitidine III MAR / 08
Ranitidine or its salts.. when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 4,500 mg of ranitidine U FEB / 07
Rasagiline or its saltsPDL I DEC / 13
RasburicasePDL I DEC / 13
Raubasine or its saltsPDL I DEC / 13
RauwolfiaPDL I DEC / 13
Regorafenib or its saltsPDL I DEC / 13
Remestemcel-LPDL I DEC / 13
RemifentanilN I JUN / 02
Remoxipride or its saltsPDL I DEC / 12
Repaglinide or its salts or derivativesPDL I DEC / 13
Rescinnamine or its saltsPDL I DEC / 13
Reserpine or its saltsPDL

for human use

I DEC / 13
ReslizumabPDL I JUN / 17
Resocortol and its derivatives.FR AUG / 06
Resocortol or its derivativesPDL I DEC / 13
RetapamulinPDL I DEC / 13
Reviparin or its saltsPDL I DEC / 13
Rho D immune globulin I FEB / 02
RibavirinPDL I DEC / 13
Ribociclib or its saltsPDL I MAY / 18
Rifabutin or its saltsPDL I DEC / 13
Rifampin or its salts or derivativesPDL I DEC / 13
Rifaximin or its salts or derivativesPDL I DEC / 13
Rilpivirine or its salts or derivativesPDL

including but not limited to rilpivirine hydrochloride

I DEC / 13
Riluzole or its saltsPDL I DEC / 13
Riociguat or its derivativesPDL I DEC / 13
RisankizumabPDL I JUL / 19
Risedronic acid or its saltsPDL I DEC / 13
Risperidone or its saltsPDL I DEC / 13
Ritodrine and its saltsPDL I DEC / 13
RitonavirPDL I DEC / 13
RituximabPDL I DEC / 13
RivaroxabanPDL I DEC / 13
Rivastigmine or its saltsPDL I DEC / 13
Rizatriptan or its saltsPDL I DEC / 13
Robenacoxib or its saltsPDL I DEC / 19
Rocuronium bromidePDL I DEC / 13
RofecoxibPDL I DEC / 13
Roflumilast or its salts or derivativesPDL I DEC / 13
RomidepsinPDL I DEC / 13
Romifidine or its saltsPDL I DEC / 13
RomiplostimPDL I DEC / 13
Ronidazole or its salts or derivativesPDL

for human use

I DEC / 13
Ropinirole or its saltsPDL I DEC / 13
Rose Bengal II SEP / 98
Rosiglitazone or its saltsPDL I DEC / 13
Rosoxacin or its saltsPDL I DEC / 13
Rosuvastatin or its saltsPDL I DEC / 13
Rotigotine or its salts or derivativesPDL I DEC / 13
Rubella vaccine II DEC / 98
Rue and its preparations and extracts II SEP / 98
Rufinamide or its derivativesPDL I DEC / 13
Rupatadine or its saltsPDL I FEB / 17
Ruxolitinib or its saltsPDL

including but not limited to ruxolitinib phosphate

I DEC / 13
Sacubitril or its saltsPDL I JAN / 16
Safinamide or its saltsPDL I FEB / 19
Salbutamol or its saltsPDL I DEC / 13
Salicylic acidPDL

when sold in topical formulations containing salicylic acid at concentrations greater than 20% and/or with a pH less than 3.0, except when sold to be applied to warts, corns or calluses

I DEC / 14
Salicylic acid and its salts when sold to be applied to warts, corns or calluses in topical preparations in concentrations greater than 40% II DEC / 14
Salicylic acid and its salts.

in topical preparations in concentrations up to and including 40% (except when sold in topical formulations containing salicylic acid at concentrations greater than 20% and/or with a pH less than 3.0 for a use other than to be applied to warts, corns and calluses)

U DEC / 14
Salmeterol or its saltsPDL I DEC / 13
Salsalate or its salts or derivativesPDL I DEC / 13
Sapropterin or its saltsPDL I DEC / 13
Saquinavir or its salts or derivativesPDL I DEC / 13
Saralasin or its saltsPDL I DEC / 13
SargramostimPDL I DEC / 13
SarilumabPDL I MAR / 17
SarolanerPDL

for veterinary use

I AUG / 16
Saxagliptin or its saltsPDL I DEC / 13
Scopolamine and its salts hyoscine, except Hyoscine butylbromide, when recommended for parenteral use II AUG / 16
Sebelipase alfaPDL I MAR / 18
SecobarbitalC1 I JUN / 02
SecukinumabPDL I MAY / 15
Selegiline or its saltsPDL I DEC / 13
Selenium in injectable form for parenteral nutrition I JAN / 03
Selexipag or its derivativesPDL I AUG / 19
SemaglutidePDL I MAR / 18
Senna and its extracts and derivatives U
Sermorelin or its saltsPDL I DEC / 13
Sertraline or its saltsPDL I DEC / 13
Sevelamer or its saltsPDL I DEC / 13
SevofluranePDL I DEC / 13
Sex hormones (natural or synthetic)PDL

for human use, including but not limited to conjugated estrogens, desogestrel, dienogest, estradiol benzoate, estradiol(hemihydrate), estrone, ethinyl estradiol, ethynodiol diacetate, etonogestrel, levonorgestrel, medroxyprogesterone acetate, norelgestromin, norethindrone acetate, norgestimate, progesterone except the following: androisoxazole, androstanolone, androstenediol or its derivatives, bolandiol or its derivatives, bolasterone, bolazine, boldenone or its derivatives, bolenol, calusterone, clostebol or its derivatives, drostanolone or its derivatives, enestebol, epitiostanol, ethylestrenol, fluoxymesterone, formebolone, furazabol, 4-Hydroxy-19-nortestosterone or its derivatives, levonorgestrel when sold as a single ingredient in an oral dosage form containing no more than 1.5 milligrams, mebolazine,mesabolone, mesterolone, metandienone, metenolone or its derivatives, methandriol, methyltestosterone or its derivatives, metribolone, mibolerone, nandrolone or its derivatives, norboletone, norclostebol or its derivatives, norethandrolone, oxabolone or its derivatives, oxandrolone, oxymesterone, oxymetholone, prasterone, quinbolone, stanozolol, stenbolone or its derivatives, testosterone or its derivatives, tibolone, tiomesterone, trenbolone or its derivatives, zeranol

I AUG / 15

2022 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled